- Home
- BTAI vs AIRE Comparison
BTAI vs AIRE Comparison
Compare BTAI & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- AIRE
- Stock Information
- Founded
- BTAI 2017
- AIRE 2021
- Country
- BTAI United States
- AIRE United States
- Employees
- BTAI 37
- AIRE N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- AIRE
- Sector
- BTAI Health Care
- AIRE
- Exchange
- BTAI Nasdaq
- AIRE Nasdaq
- Market Cap
- BTAI 41.8M
- AIRE 40.7M
- IPO Year
- BTAI 2018
- AIRE N/A
- Fundamental
- Price
- BTAI $2.12
- AIRE $0.52
- Analyst Decision
- BTAI Buy
- AIRE Buy
- Analyst Count
- BTAI 5
- AIRE 2
- Target Price
- BTAI $32.80
- AIRE $2.00
- AVG Volume (30 Days)
- BTAI 691.3K
- AIRE 7.0M
- Earning Date
- BTAI 11-12-2025
- AIRE 11-12-2025
- Dividend Yield
- BTAI N/A
- AIRE N/A
- EPS Growth
- BTAI N/A
- AIRE N/A
- EPS
- BTAI N/A
- AIRE N/A
- Revenue
- BTAI $752,000.00
- AIRE $4,149,567.00
- Revenue This Year
- BTAI N/A
- AIRE $410.32
- Revenue Next Year
- BTAI $544.99
- AIRE $166.28
- P/E Ratio
- BTAI N/A
- AIRE N/A
- Revenue Growth
- BTAI N/A
- AIRE 994.18
- 52 Week Low
- BTAI $1.17
- AIRE $0.14
- 52 Week High
- BTAI $9.26
- AIRE $4.49
- Technical
- Relative Strength Index (RSI)
- BTAI 54.12
- AIRE 48.71
- Support Level
- BTAI $1.72
- AIRE $0.41
- Resistance Level
- BTAI $2.09
- AIRE $0.65
- Average True Range (ATR)
- BTAI 0.18
- AIRE 0.06
- MACD
- BTAI 0.06
- AIRE 0.00
- Stochastic Oscillator
- BTAI 98.36
- AIRE 46.68
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.